SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/263422"
 

Search: onr:"swepub:oai:gup.ub.gu.se/263422" > Lysyl oxidase and a...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Lysyl oxidase and adipose tissue dysfunction

Pastel, E. (author)
Price, E. (author)
Sjöholm, Kajsa, 1971 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
show more...
McCulloch, L. J. (author)
Rittig, N. (author)
Liversedge, N. (author)
Knight, B. (author)
Moller, N. (author)
Svensson, Per-Arne, 1969 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Kos, K. (author)
show less...
 (creator_code:org_t)
Elsevier BV, 2018
2018
English.
In: Metabolism - Clinical and Experimental. - : Elsevier BV. - 0026-0495. ; 78, s. 118-127
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background/objectives. Lysyl oxidase (LOX) is an enzyme crucial for collagen fibre crosslinking and thus for fibrosis development. Fibrosis is characterised by a surplus of collagen fibre accumulation and is amongst others also a feature of obesity-associated dysfunctional adipose tissue (AT) which has been linked with type 2 diabetes. We hypothesised that in type 2 diabetes and obesity LOX expression and activity will be increased as a consequence of worsening AT dysfunction. This study aimed to provide a comprehensive characterisation of LOX in human AT. Methods. LOX mRNA expression was analysed in omental and abdominal subcutaneous AT obtained during elective surgery from subjects with a wide range of BMI, with and without diabetes. In addition, LOX expression was studied in subcutaneous AT before and 9.5 months after bariatric surgery. To study the mechanism of LOX changes, its expression and activity were assessed after either hypoxia, recombinant human leptin or glucose treatment of AT explants. In addition, LOX response to acute inflammation was tested after stimulation by a single injection of lipopolysaccharide versus saline solution (control) in healthy men, in vivo. Quantity of mRNA was measured by RT-qPCR. Results. LOX expression was higher in obesity and correlated with BMI whilst, in vitro, leptin at high concentrations, as a potential feedback mechanism, suppressed its expression. Neither diabetes status, nor hyperglycaemia affected LOX. Hypoxia and lipopolysaccharide-induced acute inflammation increased LOX AT expression, latter was independent of macrophage infiltration. Conclusions. Whilst LOX may not be affected by obesity-associated complications such as diabetes, our results confirm that LOX is increased by hypoxia and inflammation as underlying mechanism for its upregulation in adipose tissue with obesity. (C) 2017 Elsevier Inc. All rights reserved.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Keyword

Obesity
Fibrosis
Diabetes
Bariatric surgery
Inflammation
extracellular-matrix
insulin-resistance
metabolic profile
liver
fibrosis
weight-loss
obesity
hypoxia
expression
macrophages
adipocytes
Endocrinology & Metabolism

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view